Background
==========

Breast cancer is a major health problem, with more than 1,000,000 new cases and 370,000 deaths annually worldwide. Over the past decade, breast cancer mortality has been declining in the majority of developed countries, despite an increasing incidence. This is the combined result of better education, widespread screening programs, and more efficacious adjuvant treatments. Furthermore, improved knowledge of breast cancer biology now allows the majority of breast cancer patients to be spared the cosmetic, physical, and psychological consequences of radical treatment, including radiotherapy \[[@B1]-[@B3]\].

However, clinicians have limited instruments available for the early detection of breast cancer recurrence that results from metastases undetected at the time of the primary treatment. Molecular studies have yielded important data on breast cancer development and progression. However, no biomarkers, used alone or together, have yet proved able to definitively predict the outcome of cancer treatment, and new molecules are required that can serve as reliable indicators of the risk of cancer recurrence. Serum biomarkers are produced by body organs or tumors, and large amounts in the blood can be suggestive of tumor activity \[[@B4]\]. The only breast cancer tumor markers with demonstrated clinical utility are tumor-associated antigens, but their usefulness to follow up patients with metastatic disease can be limited \[[@B5]\].

A key challenge in breast cancer therapy is to elucidate the mechanisms involved in inducing or repressing the multiple genes required for cancer cell growth, invasion, and metastasis. Methylation-associated changes affect numerous genes in all cellular pathways \[[@B6]\], and it is widely accepted that a succession of accumulative hits in oncogenes lead to genetic lesions. The pathological features of breast cancer follow a sequential progression from the transition of a normal cell to benign proliferative hyperplasia, hyperplasia with atypia, carcinoma *in situ*, and, eventually, invasive and metastatic disease \[[@B7]\]. However, the timetable of epigenetic alterations during this progression is little understood \[[@B8]\]. Some studies have evaluated the association between gene hypermethylation and biological or clinical properties of breast tumors \[[@B9]-[@B12]\].

In breast cancer, tumor-related genes may be silenced by hypermethylation. DNA methylation, unlike other epigenetic changes, does not alter the nucleotide sequence. Hypermethylation is an epigenetic change that blocks the promoter region of a gene and results in gene silencing. When CpG islands are hypermethylated, the activity of the regulatory proteins that promote transcription is restricted due to the tightly packed nucleosomes\[[@B13]\]. Many hypermethylated genes have been reported, and silencing of these genes plays an important role in carcinogenesis, tumor progression \[[@B9],[@B14]\], and diagnosis \[[@B11],[@B15]-[@B17]\]. These hypermethylated promoters are very rarely found in normal breast. It has been suggested that aberrant hypermethylation may be useful as a biomarker, with implications for breast cancer etiology, diagnosis, and management.

The epigenetic alterations that initiate and drive tumorigenesis are promising targets for the early detection of tumor and perhaps metastasis, because they may precede clinical signs of cancer or recurrence and can be detected at very low levels \[[@B11]\]. The relationship between primary neoplasm and metastasis remains largely unknown \[[@B18]\]. There has been no comprehensive comparative study on the clinical usefulness of tumor-associated methylated DNA biomarkers in primary breast carcinoma and metastatic breast carcinoma.

Although numerous issues remain to be resolved, the quantitative measurement of circulating methylated DNA remains a promising approach to cancer risk assessment. The objective of the present study was to assess the usefulness of serum concentrations of methylated *Estrogen Receptor1 (ESR1)*and *Stratifin*(*14-3-3-σ)*gene promoters in breast cancer patients in two very different clinical situations: i) treated and with no evidence of residual or recurrent disease, and ii) treated and with detected metastatic breast cancer. We also examined whether these biomarkers add information of clinical utility during the post-treatment follow-up of breast cancer patients with metastases.

Methods
=======

Samples
-------

Blood samples (7 ml) were obtained from all study participants by venipuncture. All samples were randomly coded before processing to ensure that analysts were blinded to their origin. Samples were centrifuged at 2000 g for 10 min at room temperature, and 1-ml aliquots of serum samples were carefully transferred into new tubes. Sera were stored at -80°C until their analysis (between June 2008 and March 2009). Full clinical and pathological data were collected and known for all participants. Patient characteristics are summarized in Table [1](#T1){ref-type="table"}. This research was approved by the Institutional Ethics Committees of the Negrín Hospital, Gran Canaria and the Virgen de las Nieves Hospital, and the University of Granada, Spain, and written informed consent was obtained from all study participants.

###### 

Clinical and pathological characteristic of the breast cancer patients

  Characteristics                    Disease-Free Breast Cancer Group   Metastatic Breast Cancer Group
  ---------------------------------- ---------------------------------- --------------------------------
  **Histological type**                                                 
  Invasive ductal carcinoma          63 (81.8%)                         22 (64.7%)
  Invasive lobular carcinoma         8 (10.4%)                          6 (17.6%)
  Other invasive carcinoma           6 (7.8%)                           4 (11.4%)
  Unknown                            0                                  2 (5.8%)
                                                                        
  **Histological grade**                                                
  Grade I                            17 (22.1%)                         1 (2.9%)
  Grade II                           25 (32.5%)                         8 (23.5%)
  Grade III                          26 (33.8%)                         20 (58.8%)
  Unknown                            9 (11.7%)                          5 (14.7%)
                                                                        
  **Tumor size**                                                        
  Tis                                2 (2.6%)                           1 (2.9%)
  T1                                 40 (52.0%)                         10 (29.4%)
  T2                                 24 (31.2%)                         13 (38.2%)
  T3                                 7 (9.1%)                           5 (14.7%)
  T4                                 4 (5.2%)                           2 (5.8%)
  Tx                                 0                                  1 (2.9%)
  Unknown                                                               2 (5.8%)
                                                                        
  **Node involvement**                                                  
  N0                                 41 (53.3%)                         13 (38.2%)
  N1                                 26 (33.8%)                         8 (23.5%)
  N2                                 6 (7.8%)                           9 (26.4%)
  N3                                 3 (3.9%)                           2 (5.8%)
  Nx                                 1 (1.3%)                           2 (5.8%)
                                                                        
  **Estrogen receptor status**                                          
  Negative                           20 (25.1%)                         10 (27.7%)
  Positive                           53 (68.8%)                         21 (61.7%)
  Unknown                            4 (5.2%)                           3 (8.8%)
                                                                        
  **Progesterone receptor status**                                      
  Negative                           23 (30.0%)                         10 (29.4%)
  Positive                           50 (64.9%)                         22 (64.7%)
  Unknown                            4 (5.1%)                           2 (5.8%)
                                                                        
  **Menopause**                                                         
  Yes                                46 (62.3%)                         31 (91.1%)
  No                                 26 (33.8%)                         
  Unknown                            3 (3.9%)                           3 (8.8%)

Patient groups were formed as follows:

a\) Disease-Free Breast Cancer group \[DFBC\]. A group of 77 consecutive women surgically treated at Hospital Negrín, Gran Canaria, Spain for localized operable breast cancer without clinical or radiological evidence of distant metastases were enrolled in this study between May 2007 and December 2008.

b\) Metastatic Breast Cancer Group \[MBC\]. Samples were obtained from 34 consecutive patients with metastatic breast cancer disease treated in the Virgen de las Nieves Hospital, Granada, Spain. Samples were taken on the day that each chemotherapy cycle started, gathering a series of sequential samples for each patient from the first to the last CT cycle.

c\) Healthy Control Group, \[HC\]. An age-matched sampling approach (with FDBC group) was used, obtaining blood samples from 34 women randomly selected from among healthcare professionals of our hospital undergoing regular health examinations at the Department of Preventive Medicine.

DNA isolation
-------------

DNA from serum samples (2 ml per column) was obtained by using QIAmp DNA Blood Kit (QIAGEN Inc., CA) according to manufacturer\'s recommendations. A final elution volume of 200 μl was established. Extracted DNA was quantified spectrophotometrically. The amount of DNA recovered was measured as μg/sample. DNA samples were stored at -80°C until use.

DNA bisulfite modification and real-time QMS-PCR using SYBR green
-----------------------------------------------------------------

Identical DNA sequences that differ only in methylation status \[[@B19]\] can be amplified by means of Quantitative Methylation Specific PCR (QMS-PCR). Reagents required for the bisulfite modification of DNA were supplied in the CpGenomeTM DNA Modification Kit (Intergen, MA). The process was performed according to manufacturer\'s recommendations. Sufficient DNA can be recovered to perform MSP from an amount of starting material as small as 0.001 μg. In brief, 100 μl of extracted DNA was treated with sodium bisulfite for 16 h, thereby converting all unmethylated cytosines to uracils but leaving methylcytosines unaltered. Efficiency of DNA recovery after bisulfite modification was around 55% (data not shown). One microliter of the recovered bisulfite-treated DNA was used in each well for SYBR green reaction. Modified DNA of standards and samples are stable for at least 2 months at -80°C. A sample of bisulfite-modified universally methylated DNA genome (CpGenomeTM Universal Methylated DNA, Intergen, New York, USA), treated in the same way as patient samples and adjusted after modification to 2 μg/ml (quantified spectrophotometrically), served as internal standard to prepare serial dilutions (from 1 to 1/128) with MiliQ water to construct a Standard Curve for Real-Time QMS-PCR. Each plate contained patient samples, serial dilutions of completely methylated DNA for constructing calibration curves, positive controls, and two wells with water blanks used as negative controls. In all cases, correlation coefficients for the calibration curves were higher than 0.98, slopes ranged from 3.2 to 3.4, and PCR efficiencies were around 100%.

The reaction mixture contained 1 μl of modified serum DNA of each standard or unknown sample as template for real-time QMS-PCR, 0.5 μM of each oligonucleotide primer, 12.5 μl of 2× SYBR Green Supermix (Bio-rad), and sterile water. All PCR experiments were performed in a volume of 25 μl with 96-well plates. Primer sequences were obtained from previously published data for *stratifin*(*14-3-3-σ*) \[[@B20]\] and *estrogen receptor-*α (*ESR1*) \[[@B21]\]. The fluorescence signal of the quantitative methylation-specific PCR was generated by SYBR Green Super Mix (BioRad, Hercules, CA). PCR amplification was done by using a previously reported procedure \[[@B11]\]. The fluorescence value after QMS-PCR in each sample was converted into units of universally methylated DNA (μg/ml), which we designated *\"relative units\"*, using the corresponding PCR Standard Curve obtained from the iCycler iQ software. Results obtained in a previous study \[[@B11]\] indicated that the method was valid for this investigation.

Statistical analysis
--------------------

The associations of the two biomarkers with breast cancer presence, their capacity to discriminate between women with and without clinical and radiological evidence of breast cancer metastasis, and their post-chemotherapy behavior were analyzed in the following phases:

\(1\) Descriptive analysis of the three groups (DFBC, MBC, and HC) was performed for each biomarker, expressing results as means and standard error of the means (SEM).

\(2\) The Kruskal-Wallis test was used to study differences among groups (DFBC, MBC, and HC), and the Dunn\'s multiple comparison test was used for paired comparisons when results were significant.

\(3\) Effects of the chemotherapy on serum *ESR1*and *14-3-3-σ*levels were studied using Wilcoxon signed rank test and paired test.

\(4\) Effects of the chemotherapy on treated patients with detected metastatic breast cancer were measured according to the following scoring system: [Measurable Response]{.ul}. (MR): disappearance or decrease of all signs and symptoms of the lesions, no growth of any lesion, and no appearance of a new lesion. *Stable Disease*(SD): no significant changes in lesion size or in any tumor-related signs or symptoms. *Progression*(P): measurable increase in lesion size or appearance of new lesions. *Mortality during treatment*(MDT): patients dying during the chemotherapy period.

\(5\) Biomarker Response Ratio (BRR). The ratio of the *14-3-3-σ*level before the first chemotherapy cycle to the level just before administration of the second chemotherapy cycle was defined as the BBR.

\(6\) ROC curves: The distributions of the *14-3-3σ*ratio values corresponding to different patient populations are, at least in part, overlapped. As a consequence, the number of correct predictions of the measurable response (true positive (TP) cases identified by means of the test depends on the threshold level selected. Using different thresholds, it is possible to obtain successive pairs of false positive (FP) and TP values that can be plotted as a curve. A useful numerical parameter arising from this graph is the proportion of ROC space that lies below the ROC curve (Z).

Results
=======

Table [1](#T1){ref-type="table"} shows the general characteristics of the two patient groups studied. The groups did not differ in histological type (P \> 0.05), estrogen receptor status (P \> 0.05) or iii) progesterone receptor status (P \> 0.05). As expected, they significantly differed in tumor size (P \< 0.05), nodal involvement (P \< 0.05), and histological grade (P \< 0.05).

Median serum levels of methylated gene promoter *ESR1*did not differ among HC, DFBC, and MBC groups (P \> 0.05). Median serum *14-3-3-σ*values did not differ between HC and DFBC groups (P \> 0.05), but differed between HC and MBC groups (P \< 0.001) and between DFBC and MBC groups (P \< 0.001). Figure [1](#F1){ref-type="fig"} depicts the results obtained.

![**The box and whisker plot shows the median value and 10-90 percentiles of biomarkers, *ESR1*and *14-3-3-σ*, measured in the serum of the individuals in each of the three study groups: Healthy Controls (*HC*); Disease-Free Breast Cancer *(DFBC)*; and Metastatic Breast Cancer *(MBC)***. *14-3-3-σ*values significantly differed between the *DFBC*and *MBC*groups (Dunn test, P \> 0.0001) and between each of these and the HC group (P \< 0.001).](1471-2407-10-217-1){#F1}

Calculation of the area under the ROC curve *(Z)*for the capacity of *14-3-3-σ*to discriminate between healthy individuals and patients with breast cancer metastatic disease gave a value of *Z*= 0.925 (95% confidence interval: 0.886 to 0.964), an excellent level of accuracy.

Figure [2](#F2){ref-type="fig"} depicts *14-3-3-σ*gene values before and after the first chemotherapy cycle, showing that the chemotherapy produced a major reduction in the serum levels of *14-3-3-σ*in the MBC group. These differences have been studied using Wilcoxon signed rank test and show that the median difference in methylation after treatment is greater than zero (P = 0.0045); being the paired test also significant (P = 0.012).

![***14-3-3-σ*values measured in serum of patients with metastatic breast cancer disease before and after the first chemotherapy cycle**. Wilcoxon signed rank test, P = 0.0045.](1471-2407-10-217-2){#F2}

However, although initial levels appear to fall in most of the MBC patients, other patients show no change or an increase in levels. Figure [3](#F3){ref-type="fig"} shows those MBC patients with a continuous decline in serum *14-3-3-σ*, and Figure [4](#F4){ref-type="fig"} those patients with both rises and falls. This biomarker-based categorization has been empirically defined. Table [2](#T2){ref-type="table"} shows the contingency table that was constructed by combining this biomarker\'s response-pattern with the chemotherapy response scores. Analysis with the Pearson chi-square test gave a value of 10.23 (P = 0.017), indicating that the time course of the biomarker was determined by the clinical response to the treatment. In summary, the continuous-decline pattern of serum *14-3-3-σ*levels was associated with a positive predictive value of 65% (95% CI 38-86%), implying a favorable prognosis in two out of three patients, whereas the rise-and-fall pattern was associated with a negative predictive value of 88%, implying a poor prognosis for most of the patients with this pattern.

###### 

Patients\' summary score distribution (treatment response distribution) according to the biomarker pattern observed during the treatment time-course.

  Pattern                MR   SD   P   MDT
  ---------------------- ---- ---- --- -----
  Continuously decline   11   2    3   1
                                       
  Rise and fall          2    6    6   3

**MR:**Measurable Response; **SD:**Stable Disease; **P:**Progression; **MDT:**Mortality during treatment

![***14-3-3-σ*values measured in serum of patients with breast cancer metastatic disease before the first C(0) and successive C(1\...5) chemotherapy cycles, in patients with \"continuous decline\" biomarker pattern**.](1471-2407-10-217-3){#F3}

![***14-3-3-σ*values measured in serum of patients with breast cancer metastatic disease before the first C(0) and successive C(1\...5) chemotherapy cycles, in patients with \"rise-and-fall\" biomarker pattern**.](1471-2407-10-217-4){#F4}

Finally, we calculated the ratio of the *14-3-3-σ*level before the first chemotherapy cycle to the level just before administration of the second chemotherapy cycle for the \"continuous decline\" and \"rise-and-fall\" groups (figure [5](#F5){ref-type="fig"}). The median values are: 5.606 and 1.694, respectively and the medians, Mann Whitney test, are significantly different (P = 0.0034).

![**Discriminatory power of the biomarker response ratio \[*14-3-3-σ BRR*\] to predict the outcome in patients with metastatic breast cancer treated with chemotherapy**. A: Comparison between treatment outcomes; B: ROC curve.](1471-2407-10-217-5){#F5}

Discussion
==========

Accurate prognosis and predictive factors are necessary for the optimum management of patients with cancer and are especially important in breast cancer, because of its widely varying outcomes and the availability of potentially beneficial systemic adjuvant therapies. The definitive assessment of the clinical value of a predictive factor is a long process \[[@B4]\], but the use of an unbiased genome-wide approach has permitted the rapid identification of a number of genes that strongly predict a poor clinical outcome \[[@B22]\]. The identification of mutations and/or epigenetic alterations in cancer may be useful to develop novel, more effective biomarkers and therapies in breast and colon cancer \[[@B22]\]. In breast cancer, promoter hypermethylation has been reported for various genes that cover most cell functions \[[@B11],[@B15],[@B17],[@B23],[@B24]\].

Estrogen receptor status is an important factor in the diagnosis and prognosis of breast cancer. A previous study by our group found a significant difference in serum values of *ESR1*and *14-3-3-σ*gene promoters between breast cancer patients and healthy controls \[[@B11]\]. The present study also found a significant difference in serum methylated *14-3-3-σ*gene promoter between metastatic breast cancer patients and healthy controls. In contrast, however, *ESR1*appeared to be unmethylated in the present patients with metastatic breast cancer. Theoretically, *ESR1*is considered to be preferentially methylated in tumors because its inactivation confers a selective clonal advantage\[[@B25]\]. It is possible that the specific environmental and nutritional setting of breast cancer metastases produces changes in this epigenetic alteration. However, further in-depth study is required to explain this intriguing finding. Reports of differences in methylation pattern between primary and metastatic breast cancer \[[@B18]\] may indicate that therapeutic targets in primary breast cancer are not be the same as targets in metastatic sites.

14-3-3 proteins are crucial in a wide variety of cell responses, including DNA damage checkpoints and apoptosis \[[@B26]\]. Disruption of the G2-M checkpoint also appears to contribute to the change in the sensitivity of cells to chemo- and radiotherapy \[[@B27],[@B28]\]. 14-3-3 sigma sequesters the cdc2-cyclin B1 complex in the cytoplasm, resulting in G2 arrest. Among the genes involved in the G2-M checkpoint, *14-3-3σ*, a transcriptional target of p53, is frequently silenced by DNA methylation of the *14-3-3σ*gene promoter or by induction of estrogen-responsive ubiquitin ligase that specifically targets *14-3-3σ*for proteosomal degradation \[[@B23],[@B29]\]. The inactivation and reduced expression of 14-3-3σ have been reported in various cancers, including breast cancer \[[@B16],[@B26],[@B30]\]. To date, the sigma isoform of 14-3-3 proteins has been the isoform most directly implicated in carcinogenesis and is recognized as a tumor-suppressor gene \[[@B31]\]. Although the molecular basis for the tumor-suppressor function of 14-3-3σ is unknown \[[@B26]\], it has been suggested that 14-3-3σ is a critical regulator of G2-M \[[@B32]\]. It has also been demonstrated that endogenous 14-3-3σ preferentially forms homodimers in cells \[[@B33]\]. Knocking out *14-3-3σ*in cancer cells leads to mitotic catastrophe and cell death from DNA damage due to the absence of G2-M arrest \[[@B34]\]. Moreover, the highly conserved human *14-3-3*gene family encodes proteins with either tumor-promoting or tumor-suppressing activities, suggesting that the cellular balance among different 14-3-3 isoforms is crucial for the proper functioning of cells \[[@B32]\]. 14-3-3 proteins have been found in primary breast cancer, enhancing its biological activity \[[@B35]\]. The structure of the p53 C-terminus bound to the adaptor protein 14-3-3 has been recently described, providing a rationale for the observed stabilizing effect of 14-3-3 binding \[[@B36]\]. Consistent with these data, the G2-M checkpoint is impaired in cancer cell lines that show methylation of *14-3-3 σ*, while restoration of the expression of these genes using 5-aza-dC restores G2-M arrest induced by DNA damage \[[@B37]\]. This molecule also contributes to mitotic catastrophe in carcinoma cells treated with chemotherapy agents \[[@B38]\].

Results of a recent study \[[@B39]\] showed that 14-3-3 and HSP70 expression may be useful as biomarkers and targets for the diagnosis and treatment of human triple-negative breast cancer. Breast cancer metastasis is the main cause of treatment failure, and the goal of adjuvant therapy is to eliminate disseminated tumor cells after complete removal of the tumor. However no tool is available to monitor its efficacy \[[@B11]\]. Response to adjuvant treatment is usually evaluated retrospectively based on recurrence and survival rates. Therefore, the identification of metastasis biomarkers at an early stage may contribute to the early diagnosis and treatment of breast cancer patients. There is increasing recognition of the importance of epigenetic changes in the metastatic process. Cells may acquire an epi-genotype that allows them to disseminate from the primary tumor mass or survive and proliferate at a secondary tissue site \[[@B40]\]. Overall, these results offer evidence of a difference in protein profile between metastatic and primary breast cancer.

The expression profile of the metastatic tumor is known to differ between primary tumor and heterogeneous metastasis \[[@B39]\]. The present findings show that breast cancer methylation profiling might yield biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. Thus, we found that ROC analysis of serum levels of *14-3-3-σ*methylated gene-promoter discriminated between healthy individuals and metastatic breast cancer patients with a sensitivity of 81% (95% CI: 74.0 - 86.8) and a specificity of 96.2% (95% CI: 80.45 - 99.9), making this biomarker a candidate for use in metastasis screening in the follow-up of treated breast cancer patients. It would be of special interest to investigate whether the elevated post-surgical serum *14-3-3-σ*levels in some of the present patients (DFBC group) and in our previous study \[[@B11]\] indicate a risk of metastatic cancer or tumor recurrence. Although this type of investigation requires a prolonged follow-up \[[@B4]\], identification of this biomarker as a risk factor and its correlation with other clinical factors may lead to improvements in breast cancer treatment.

14-3-3-σ proteins are known to be crucial in a wide variety of cell responses, including cell cycle progression, DNA damage checkpoints, and apoptosis \[[@B26]\], and *14-3-3-σ*hypermethylation is a significant event in primary breast cancer \[[@B41]\]. However, its impact on tumor progression and its potential as a predictive factor remain unknown. Because 14-3-3-σ proteins regulate normal cell processes, the loss of their expression (mainly by hypermethylation of *14-3-3-σ*gene promoter) may be implicated in breast cancer progression \[[@B31],[@B42]\]. This hypothesis is supported by our data, since hypermethylation of *14-3-3-σ*was significantly associated with the response to metastatic breast cancer treatment. We calculated BRR values for the \"continuous decline\" and \"rise-and-fall\" groups (values plotted in Figure [5A](#F5){ref-type="fig"}). Analysis by unpaired t-test with Welch\'s correction showed a significant difference in mean values between these groups (P = 0.021). Subsequent ROC analysis, considering the \"continuous decline group\" as controls and the rise-and-fall group as cases (Figure [5B](#F5){ref-type="fig"}), showed a sensitivity of 75% (95% CI: 47.6 - 86.7) and a specificity of 66.7% (95% CI: 41.0 - 86.7) to discriminate between the groups for a cut-off level of BRR = 2.39.

The area under the ROC curve (Z = 0.804 ± 0.074) indicates that this test is a good approach to post-treatment prognosis and supports the very recent idea that 14-3-3 proteins may be related to breast cancer metastasis and evolution \[[@B43]\]. However, a small amount of *14-3-3-σ*methylated was detected in sera from healthy controls \[[@B11]\], which may be explained by presence of occult benign breast disease, although other possible sources of this DNA include: normal tissues, which show higher methylation values with increasing age\[[@B44]\]; leukocytes \[[@B23]\], or breast benign disease \[[@B41]\]. The above findings raise some questions about the utilization of *14-3-3-σ*gene promoter in DNA extracted from serum for metastasis screening in the follow-up of treated breast cancer patients. Further research is warranted to elucidate this issue and to establish the impact of *14-3-3σ*on tumor progression and its potential to predict the response to treatment of metastatic breast cancer.

Conclusions
===========

There are numerous promising treatments for advanced breast cancer now in phase III trial, and there is an urgent need to establish sensitive end-points that can be assessed earlier than overall survival \[[@B45]\]. Although further research is required to establish the link between *14-3-3-σ*hypermethylated gene promoter measured in the serum of breast cancer patients and the response to chemotherapy, including control of symptoms, avoidance of adverse effects, and improvement in quality of life, important aspects in the approaching era of personalized medicine, this biomarker may be potentially useful to monitor disease status and treatment response.
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